Depo Provera Appears to Increase Risk for Chlamydial and Gonococcal Infections -- August 23, 2004

Women using the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appear to have a three-fold increased risk of acquiring the sexually transmitted infections chlamydia and gonorrhea when compared to women not using a hormonal contraceptive, according to a study conducted by FHI researchers and colleagues. For more information about the study, which appears in the September Sexually Transmitted Diseases and which was jointly funded by the National Institute of Child Health and Human Development and the U.S. Agency for International Development, click here. For more information about hormonal contraceptive use and sexually transmitted infections, click here. For an overview of the latest research related to hormonal contraception and HIV, click here.

Family Health International is dedicated to improving lives, knowledge and understanding worldwide through a highly diversified program of research, education and services in family health and HIV/AIDS prevention, care and treatment. Since its inception in 1971, FHI has formed partnerships with national governments and local communities throughout the developing world to support lasting improvements in the health of individuals and the effectiveness of entire health systems. FHI has a staff of 1200 and offices in 40 countries.